Clinical Trials
Clinical trials have focused on the development of combined-modality treatment approaches involving novel chemotherapy agents, radiotherapy techniques and surgical approaches. These protocols represent a major collaborative effort with the departments of Thoracic/Head and Neck Medical Oncology, Gastrointestinal Oncology and Digestive Diseases and Radiation Oncology.
Current protocols for lung cancer include both preoperative and postoperative adjuvant chemotherapy with novel agents.
Protocols combining chemotherapy, radiotherapy and surgery are being evaluated for esophageal cancer.
A novel strategy of pulmonary perfusion with doxorubicin for sarcomatous lung metastases is being evaluated.
A major collaboration with the Thoracic/Head and Neck Medical Oncology department is directed toward chemoprevention of second primary cancers in patients with early-stage lung cancer. The Thoracic and Cardiovascular Surgery department has completed clinical trials to evaluate replacement of the p53 tumor suppressor gene by delivering a functional p53 tumor suppressor via retroviral and adenoviral vectors in patients with non-small cell lung cancer. New trials combining p53 gene replacement are planned in combination with radiotherapy and chemotherapy in collaboration with the Thoracic/Head and Neck Medical Oncology department.
If you are interested in participating in one of these clinical trials, please call the Information Line toll-free at 1-800-MDA-06789 or visit the UT MD Anderson Clinical Trials site.
Clinical Trials
Other departments, like Thoracic Head & Neck Medical Oncology, Radiation Oncology and GI Medical Oncology, may have available clinical trials open for lung cancer, esophageal cancer and mesothelioma.
Active Clinical Trials
Lung Cancer
Study #: 2014-0938
Longitudinal Biospecimen Acquisition for All Tumor Types And At-Risk Tissue
Co-Investigator: Andrew Futreal, Ph.D.
Study #: 2017-0311
Randomized Phase 3 Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients with Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS
NCT033918169
Co-Investigator: Stephen Swisher, M.D.
Study #: 2018-0301
Ablation of Lung Lesions Using Microwave Energy (ALLUME)
NCT04430725
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2018-0500
Pulmonary Artery Pressure (PAP) measurement by Endobronchial Ultrasound (EBUS)
Principal Investigator: Reza Mehran, M.D.
Study #: 2018-0678
Pilot Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
NCT03784326
Principal Investigator: Mariela Blum, M.D.
Study #: 2019-0171
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
NCT04199026
Principal Investigator: Joseph Ludwig, M.D.
Study #: 2019-0334
Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
NCT03802981
Study #: 2020-0453
Ambulation to Improve Recovery with wearable TECHnology (AIRTECH) study
NCT04783168
Principal Investigator: Garrett Walsh, M.D.
Study #: 2020-0674
Single arm Phase 2 trial using canakinumab for the prevention of lung Cancer (Can-Prevent-Lung)
NCT04789681
Co-Investigator: Jianjun Zhang, M.D., Ph.D.
Study #: 2020-0696
The Rise in Robotic Atypical Segmentectomies: A Large Cancer Center Experience
NCT04644952
Principal Investigator: David Rice, M.D.
Study #: 2020-1232
CHIO3 Trial: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
NCT04062708
Principal Investigator: Reza Mehran, M.D.
Study #: 2021-1143
Home Monitoring of Pulmonary Function Tests following Lung Resection Clinical Trial (HOPeFUL Study)
Principal Investigator: Ara Vaporciyan, M.D.
Study #: 2021-1144
Financial Toxicity in Patients Undergoing Management for Thoracic Cancer: A Cross-sectional Survey on the Impact of Out-of-Pocket Costs, Lost Wages and Unemployment
Principal Investigator: Ravi Rajaram, M.D.
Study #: 2022-0012
A Prospective, Multi-Center Investigation of the da Vinci SP® Surgical System in Pulmonary Lobectomy and Thymectomy for Benign and Malignant Disease
NCT05150210
Principal Investigator: David C. Rice, M.D.
Study #: 2022-0229
Comparing the Effectiveness of Surgery versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer (SORT Trial)
NCT05183932
Principal Investigator: Ara Vaporciyan, M.D.
Study #: 2022-0256COGAOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
NCT05235165
Co-Investigator: Najat C. Daw, M.D.
Study #: 2023-0690PULS
An international collaboration for the collection and assessment of data from patients with PULmonary artery Sarcoma for a better management and understanding of this rare disease.
Principal Investigator: David C. Rice, M.D.
Study #: 2024-0199
SR2204: A Randomized Phase 3 Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers
NCT06196008
Study #: 2024-1114
Molecular Profiling of Bronchoscopy Samples for Diagnosis and Molecular Subtyping of Lung Nodules for Personalized Interception
Co-Investigator: Ara Vaporciyan, M.D.
Study #: ECOG-ACRIN EA5142
ECOG-ACRIN EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase 3 Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
NCT02595944
Co-Investigator: Don Gibbons, M.D., Ph.D.
Esophageal Cancer
Study #: 2016-0972
A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery versus Systemic Therapy for Patients with Esophageal or Gastric Cancer with Oligometastases
NCT03161522
Co-Investigator: Quynh-Nhu Nguyen, M.D., M.H.C.M.
Study #: PA11-0891
Treatment Patterns, Outcomes, and Staging Deficiencies in cT2N0 Esophageal Cancer
Principal Investigator: Wayne Hofstetter, M.D.
Study #: PA12-0209
Pathologic and Molecular Predictors of Nodal Metastasis and Clinical Outcome in Surgically Resected Esophageal Adenocarcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2019-1198
Distribution of lymph node metastases in esophageal carcinoma [TIGER]
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2019-1253
A Phase 1 Study of NBTXR3 activated by Radiotherapy with concurrent Chemotherapy for Adenocarcinoma of the Esophagus
NCT04615013
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-0122
A Phase 1 Study of NBTXR3 activated by Radiotherapy with concurrent Chemotherapy for Adenocarcinoma of the Esophagus
NCT04522336
Co-Investigator: Wayne Hofstetter, M.D.
Study #: 2020-1199
Management of Nodal Recurrence after Curative Treatment of Esophageal Cancer
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-0193
Outcomes after Bimodality versus Trimodality Therapy for Esophageal Squamous Cell Carcinoma
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2020-0599
Risk Factors and treatment options for metachronic brain metastases after esophagectomy for esophageal cancer: a multicentric retrospective cohort study
Principal Investigator: Wayne Hofstetter, M.D.
Study #: 2021-0565
Clinical Outcomes in Patients with Esophageal Cancer With Skip Lesions
Principal Investigator: Wayne Hofstetter, M.D.
Study #: NRG-GI006
NRG-GI006: Phase 3 Randomized Trial Of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) For The Treatment Of Esophageal Cancer
NCT03801876
Co-Investigator: Reza J. Mehran, M.D.
Mesothelioma
Study # 2019-0943
Neoadjuvant immune checkpoint blockade in Resectable Malignant Pleural Mesothelioma
NCT03918252
Principal Investigator: Reza J. Mehran, M.D.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.